RECRUITING
I'm interested ...!!
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
Conditions:
🦠 COVID-19 🦠 Diabete Mellitus
🗓️ Study Start (Actual) 10 July 2023
🗓️ Primary Completion (Estimated) June 2025
✅ Study Completion (Estimated) August 2026
👥 Enrollment (Estimated) 213
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 San Antonio, Texas, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Body Mass index (BMI) \< 40 kg/m2

    Exclusion Criteria:

    • * History of diabetes prior to SARS-CoV-2 infection
    • * Took medications used to treat diabetes prior to SARS-CoV-2 infection
    • * History of myocardial infarction or stroke within 6 months
    • * History of major organ system disease prior to COVID-19 infection
Ages Eligible for Study: 18 Years to 75 Years (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 17 May 2023
  • First Submitted that Met QC Criteria 17 May 2023
  • First Posted 19 May 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 13 July 2023
  • Last Update Posted 14 July 2023
  • Last Verified July 2023
I'm interested ...!!